BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
Status:
Terminated
Trial end date:
2017-09-06
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the ability of bone marrow transplantation
(BMT) and high-dose post-transplantation cyclophosphamide (PT/Cy) to induce renal allograft
tolerance and thus enable discontinuation of immunosuppressive therapy in haploidentical
living related donor renal transplant recipients.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)